NEW YORK (GenomeWeb) — Precipio said today that the University of Cincinnati Medical Center (UCMC) will use its ICE-COLD PCR (ICP) mutation enrichment technology in a study screening for clinically actionable mutations in non-small cell lung cancer (NSCLC) patients.